导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.75% | 4120/4773 |
| 近一周 | -4.40% | 4978/5462 |
| 近一月 | -4.64% | 2611/5421 |
| 近一季 | -2.03% | 1141/5209 |
| 近半年 | -12.81% | 3802/4920 |
| 近一年 | -22.37% | 3982/4366 |
| 近两年 | 1.56% | 2868/2954 |
| 近三年 | -30.57% | 2216/2253 |
| 成立以来 | 114.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.75% 3934/4961 |
-13.92% 4530/5312 |
- - |
- - |
| 2025 | -5.37% 3372/4813 |
-1.40% 2659/3635 |
-3.33% 3427/4076 |
3.69% 3727/4524 |
-4.25% 3427/4813 |
| 2024 | -3.96% 2227/3463 |
-1.03% 1171/2808 |
-12.14% 2590/3014 |
17.19% 1246/3129 |
-5.75% 2588/3463 |
| 2023 | -18.18% 1789/2656 |
3.18% 1245/2280 |
-13.20% 2204/2385 |
-1.32% 504/2515 |
-7.42% 2144/2655 |
| 2022 | -13.52% 333/2207 |
-20.33% 1538/1919 |
19.73% 76/2016 |
-11.78% 581/2113 |
2.77% 841/2208 |
| 2021 | -7.04% 1026/1822 |
-9.88% 1112/1255 |
9.68% 533/1330 |
-10.94% 1248/1466 |
5.60% 282/1822 |
| 2020 | 92.13% 21/1250 |
0.21% 168/1028 |
26.60% 144/1067 |
21.23% 43/1164 |
24.93% 31/1184 |
| 2019 | 60.98% 51/1092 |
39.12% 55/739 |
9.96% 9/788 |
0.90% 446/850 |
4.29% 814/918 |
| 2018 | -18.72% 149/834 |
- - |
8.83% 5/631 |
-5.16% 364/660 |
-15.73% 619/682 |
| 2017 | 36.31% 30/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.66% 93/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证食品饮料ETF联接C VS. 长安沪深300非周期A(740101) |